Brokerages forecast that Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will post ($0.37) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Galmed Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.27). Galmed Pharmaceuticals reported earnings of ($0.39) per share in the same quarter last year, which would indicate a positive year over year growth rate of 5.1%. The company is expected to issue its next earnings results on Wednesday, August 2nd.
According to Zacks, analysts expect that Galmed Pharmaceuticals will report full-year earnings of ($1.37) per share for the current year, with EPS estimates ranging from ($1.65) to ($1.06). For the next financial year, analysts expect that the firm will post earnings of ($1.59) per share, with EPS estimates ranging from ($1.74) to ($1.35). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Galmed Pharmaceuticals.
Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.13. The company had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.29 million.
A number of equities research analysts recently weighed in on GLMD shares. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a report on Tuesday, March 28th. Maxim Group restated a “buy” rating and issued a $9.00 price target on shares of Galmed Pharmaceuticals in a report on Friday, March 24th. ValuEngine upgraded Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 17th. Finally, HC Wainwright lowered their price target on Galmed Pharmaceuticals from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, March 28th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $11.56.
TRADEMARK VIOLATION NOTICE: “Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Expected to Announce Earnings of -$0.37 Per Share” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2017/08/12/galmed-pharmaceuticals-ltd-nasdaqglmd-expected-to-announce-earnings-of-0-37-per-share-updated-updated-updated.html.
An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. KCG Holdings Inc. bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned about 0.17% of Galmed Pharmaceuticals at the end of the most recent quarter. 8.02% of the stock is currently owned by institutional investors.
Shares of Galmed Pharmaceuticals (NASDAQ:GLMD) traded down 4.67% during mid-day trading on Friday, reaching $6.53. The company’s stock had a trading volume of 24,663 shares. The company’s 50 day moving average price is $5.40 and its 200-day moving average price is $4.69. The company’s market capitalization is $79.46 million. Galmed Pharmaceuticals has a 1-year low of $2.78 and a 1-year high of $7.32.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Galmed Pharmaceuticals Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galmed Pharmaceuticals Ltd. and related companies.